United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer Inc. and BioNTech on Friday submitted an application for an emergency use authorization for their trial COVID-19 vaccine candidate, making their vaccine candidate the first in line with U.S. regulators. The two companies had said earlier Friday that the submission to the Food and Drug Administration was coming.

Pfizer, BioNTech make it official: COVID-19 vaccine EUA submitted

AstraZeneca

Johnson & Johnson

Moderna

The pharmaceutical industry has succeeded in doing its job in manufacturing multiple vaccines for the novel coronavirus, and it's "now in the hands" of government authorities to manage the distribution, Emily Field, head of European pharmaceutical research at Barclays, Emily Field said Friday on CNBC's "Squawk Box Europe." Price Not A Factor: Early indications suggest AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson's (NYSE: JNJ) vaccine will cost $3 to $5, while pricing for Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) could reach $40 on the high end.

Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst

Shares of BioNTech and Pfizer rose after the pharmaceutical companies announced they would submit their coronavirus vaccine to U.S. regulators Friday, the first drugmakers to seek approval. The post BioNTech, Pfizer Ready To Submit Coronavirus Vaccine To FDA appeared first on Investor's Business Daily.

BioNTech, Pfizer Ready To Submit Coronavirus Vaccine To FDA

Emergency Use Authorization could pave the way for a rapid rollout of their coronavirus vaccine.

Why Pfizer and BioNTech Stocks Rose Today

Emergency Use Authorization could enable shipments to high-risk populations in the U.S. in December.

Pfizer and BioNTech Will Ask the FDA to Authorize Their Coronavirus Vaccine Today

Pfizer and BioNTech gained on Friday after saying they would submit their COVID-19 vaccine candidate to the FDA today for Emergency Use Authorization. Phase III trial results released earlier this month were encouraging, with the vaccine demonstrating an efficacy rate of 95% in a trial with 44,000 participants. 

Pfizer, BioNTech gain after saying they'll submit their COVID-19 vaccine to the FDA for emergency approval (PFE, BNTX)

Signaling that Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) are nearing the finish line, the companies announced plans Friday to apply for emergency use authorization for the coronavirus vaccine candidate BNT162b2. First To File: The filing means the vaccine could be available for high-risk populations in the U.S. by the middle or end of December.

Pfizer, BioNTech File First For Emergency Use Authorization Of Coronavirus Vaccine

Clinical trials show the vaccine to be 95% effective at preventing Covid-19.

Pfizer, BioNTech To Seek Emergency Approval For Covid-19 Vaccine On Friday

AbbVie

Bristol-Myers

Merck

Snowflake

T-Mobile US

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.

Warren Buffett Just Bought These Stocks

Pfizer and BioNTech said they will ask the feds for emergency approval of their experimental coronavirus vaccine on Friday.

Pfizer to request emergency FDA approval for its COVID-19 vaccine

Pfizer/BioNTech said they intend to submit applications to other regulatory agencies worldwide in coming days.

Pfizer/BioNTech to seek emergency authorization of Covid-19 vaccine Friday

Two of the companies behind one of the leading COVID-19 vaccine candidates will seek approval from the U.S. Food and Drug Administration for emergency use authorization (EUA) of their preventative treatment with an application to be delivered today. Pfizer and BioNTech, who revealed earlier this week that their vaccine was 95% effective based on Phase […]

Pfizer and BioNTech to submit request for emergency use approval of their COVID-19 vaccine today

However, even if the EUA is granted, the chances of the average American receiving Pfizer's COVID-19 vaccine in 2020 is slim. Just days after announcing their COVID-19 vaccine has an efficacy rating of at least 95%, Pfizer has announced that they plan to ask the Food and Drug Administration for emergency use authorization (EUA) today, reports CNBC.

Pfizer COVID-19 vaccine: The timeline now that FDA emergency use has been requested

Shares of Pfizer Inc. gained 1.4% in premarket trading on Friday after it announced plans with BioNTech to submit an application later in the day for an emergency use authorization for their experimental COVID-19 vaccine candidate. BioNTech's stock jumped 6.9% before the market opened.

BioNTech, Pfizer say they plan to submit COVID-19 vaccine application on Friday

Pfizer and BioNTech will on Friday ask regulators to sign off on the emergency use of their coronavirus vaccine, a step that could allow the shot to be given more widely. Pfizer said Friday that it was preparing to file for an emergency use authorization with the US Food and Drug Administration, days after announcing that the vaccine was 95% effective at preventing COVID-19 in a late-stage trial.

Pfizer is about to ask the FDA to authorize its coronavirus vaccine, a critical step before it can be given to more people

Pfizer Inc said on Friday it has applied to U.S. health regulators for emergency use authorization (EUA) of its COVID-19 vaccine, a major step toward providing protection against the new coronavirus for pandemic-weary Americans.

Pfizer applies for U.S. emergency use for COVID-19 vaccine

In an attempt to “synchronize” COVID-19 vaccine distribution at par with the U.S., the European Union is deliberating the idea of granting  Pfizer Inc (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), a conditional marketing authorization, Bloomberg reports. What Happened: The European authority is holding constant talks with the U.S. Food and Drug Administration to evaluate and assess the vaccine's efficacy, Ursula von der Leyen, President of the European Commission, told Bloomberg.

Pfizer, Moderna COVID-19 Vaccines Could Get Limited EU Approval Before Year-End: Report

The FDA process is expected to take a few weeks, and an advisory committee meeting to review the vaccine has been tentatively scheduled for early December.

Pfizer and BioNTech to request emergency authorization from FDA for Covid-19 vaccine.

Zoom Video

Dr. Jeremy Brown knows a lot about pandemics. Here's what he thinks about the exciting trial data coming from Pfizer and BioNTech.

Doctor and Pandemic Expert Shares What Investors Need To Know About Coronavirus Vaccines

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. The submission is based on a vaccine efficacy rate of 95% (p

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

Pfizer and BioNTech are submitting an emergency authorisation request in the US which could allow its coronavirus vaccine to be used to treat high-risk populations in the country by mid-December.

Pfizer requests emergency authorisation for coronavirus vaccine in US

CureVac B.V

The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks told Reuters.

Exclusive: EU could pay over $10 billion for Pfizer and CureVac vaccines - source

FDA approval for emergency usage is the first step to getting the COVID-19 vaccine to the public.

Pfizer, Moderna to file FDA COVID-19 vaccine emergency usage as soon as Friday

Health and Human Services Secretary Alex Azar said Thursday that Pfizer is expected to file an application to the FDA for emergency use of its coronavirus vaccine on Friday, with Moderna soon to follow.

HHS Secretary Azar says Pfizer is expected to file FDA application for coronavirus vaccine Friday with Moderna soon to follow

Hess

Marathon Oil

Occidental Petroleum

Another wave of Covid-19 could result in a double-dip recession, hurting leveraged oil companies. Put these on your list of stocks to sell.

News for Pfizer Stock (PFE)